Form DEFA14A ANAVEX LIFE SCIENCES

September 14, 2026 9:06 AM EDT

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION

 


Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant

 

Filed by a Party other than the Registrant

 

Check the appropriate box:
  Preliminary Proxy Statement
  Confidential, For Use of the Commission Only (As permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under § 240.14a-12

 

ANAVEX LIFE SCIENCES CORP.

 

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

  No fee required
  Fee paid previously with preliminary materials
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

On September 14, 2026, Anavex Life Sciences Corp. (“Anavex” or the “Company”) issued a Press Release announcing that proxy advisory firm Institutional Shareholder Services Inc. has recommended that Anavex stockholders vote “FOR” all six of the Company’s director nominees at the Company’s 2026 Annual Meeting of Stockholders scheduled for September 24, 2026. A copy of the Press Release is attached hereto.

 

 

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings